—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
Cancer Biotherapy and Radiopharmaceuticals《癌症生物治疗与放射性药物》
年10期 - 美国
  • Cancer Biotherapy and Radiopharmaceuticals《癌症生物治疗与放射性药物》
  • SCIE外文期刊
  • 期发文量7
  • 国人占比71.43%
  • 知网外文库,维普目次
  • 投稿方式--官网投稿
  • 期刊属性

  • 中科分区:4区
    OA期刊:混合
  • 综述期刊:
    TOP期刊:
  • 期均国文:5
    环比增速:25.00%
  • 期刊信息

  • 研究方向:医学-MEDICINE, RESEARCH EXPERIMENTAL医学:研究与实验;ONCOLOGY肿瘤学;PHARMACOLOGY PHARMACY药学;RADIOLOGY, NUCLEAR MEDICINE MEDICAL IMAGING核医学
  • 国际刊号:ISSN 1084-9785;EISSN 1557-8852
  • 期刊语言:英语
    出版地区:美国
  • 投稿网址:https://mc.manuscriptcentral.com/cancerbiotherapy
  • 电子邮箱:
  • 期刊官网:https://home.liebertpub.com/publications/cancer-biotherapy-and-radiopharmaceuticals/8/
  • 作者指南:
  • 出版商网址:http://www.liebertpub.com/
  • 出版地址:140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, USA, NY, 10801
  • 期刊简介:Cancer Biotherapy and Radiopharmaceuticals《癌症生物治疗与放射性药物》(一年10期). Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.

  • 万维提示


  • 1、投稿方式:在线投稿。

    2、期刊网址:

    https://home.liebertpub.com/publications/cancer-biotherapy-and-radiopharmaceuticals/8/

    3、投稿网址:

    https://mc.manuscriptcentral.com/cancerbiotherapy

    4、官网邮箱:kcloudhansen@liebertpub.com(编辑部)

    5、期刊刊期:一年出版10期。

    2022111日星期二

                                  

     

    投稿须知【官网信息】

     

    Cancer Biotherapy and Radiopharmaceuticals

    For Authors

    Manuscript Submission Guidelines

    View General Guidelines

    Journal Information

    Manuscript Submission Site: https://mc.manuscriptcentral.com/cancerbiotherapy

    Editorial Office Contact: kcloudhansen@liebertpub.com

    Support Contact: prosupport@liebertpub.com

    Journal Model: Hybrid (Open Acess Option)

    Blinding: Single Blind

    File formatting requirement stage: Upon submission

    Instant Online Option (immediate publication of accepted version): No

    Submission Fee: $50.00. Click here to purchase your submission token.

    Average time to initial decision: 18 days

    About the Journal

    Cancer Biotherapy and Radiopharmaceuticals invites original contributions on all research related to furthering the study of cancer therapeutics and research at the intersection of that therapy with radiopharmaceuticals for both diagnostic and therapeutic applications. The mission of the journal is to communicate advances in fields including biotherapy, targeted drug and radionuclide delivery, nanotechnology, and studies that advance the understanding of the mechanism of action and response of cancer to therapeutics. It is the expectation of this journal that all of the biological, chemical, and radiochemical tools be rigorously applied, characterized appropriately with the results of the studies in submitted manuscripts supported by the application of both rigorous controls and wherever appropriate, statistics. If you are uncertain if your work falls within the scope of the journal, please email the title and abstract of the paper to the editorial office prior to submission.

    Manuscript Types and Guidelines

    Original Articles

    Comprehensive complete accounts of significant studies should be submitted as Original Articles (the majority of submissions fall under this category).

    3,000-word limit

    Structured abstract of no more than 200 words

    Maximum total of ten (10) figures and/or tables

    Maximum of 100 references

    Uncropped western blots must be uploaded as supplemental data.

     

    Review Articles

    Suitable review articles that fall within the purview of the journal may introduce readers to topics of current interest or provide comprehensive updates to specific fields and topics that fall within the purview of the journal. Reviews should provide a concise overview of fundamental topics and translational issues. Reviews should be accessible to the broad readership of Cancer Biotherapy and Radiopharmaceuticals.

    5,000-word limit

    Abstract of no more than 250 words

    Maximum total of ten (10) figures and/or tables

    Maximum of 150 references

    Uncropped western blots must be uploaded as supplemental data.

     

    Short Reports

    Technical Notes or Short Reports are a third category that is intended to provide publication of brief transformative techniques and methodology that researchers will potentially find of value and use in their respective laboratories. These are, by their nature, intended to be brief and concise (2-3 journal pages), yet fully informative to facilitate immediate use of the related information.

    1,200-word limit

    Abstract of no more than 100 words

    Maximum total of five (5) figures and/or tables

    Maximum of 10 references

    Uncropped western blots must be uploaded as supplemental data.

    ……

    更多详情:

    https://home.liebertpub.com/publications/cancer-biotherapy-and-radiopharmaceuticals/8/for-authors







欢迎点评!让信息更透明,使投稿更轻松!
  • 审稿时间:
    是否录用:
  • 见刊周期:
    查重要求:
  • 有无课题:
    有无回复:
  • 我的学历:
    我的职称:
  • 审稿费用:
    版面费用:
  • 稿       费:
    稿件字数:
  • 投稿难度:
  • 该刊可发:
  • 投稿主题:
匿名: 验证码: 点击切换验证码
    评分:0

    验证码: 点击切换验证码